GPR83 and depressive disorder: By using a composite behavioral and circuit biomarker to identify a subgroup of patients with depression and targeting the α2A receptor with GIR, we demonstrate for the first improvements in neural circuit function, clinical outcomes, cognitive performance, and psychosocial outcomes.